01-3540
6-氨基己酸
SAJ special grade, ≥99.0%
别名:
ε-氨基己酸, 6-氨基己酸, EACA
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
线性分子式:
H2N(CH2)5CO2H
化学文摘社编号:
分子量:
131.17
EC Number:
200-469-3
UNSPSC Code:
12352116
PubChem Substance ID:
Beilstein/REAXYS Number:
906872
MDL number:
grade
SAJ special grade
assay
≥99.0%
form
solid
availability
available only in Japan
mp
207 °C, 207-209 °C (dec.) (lit.)
solubility
water: soluble
application(s)
peptide synthesis
SMILES string
NCCCCCC(O)=O
InChI
1S/C6H13NO2/c7-5-3-1-2-4-6(8)9/h1-5,7H2,(H,8,9)
InChI key
SLXKOJJOQWFEFD-UHFFFAOYSA-N
Gene Information
human ... PLAT(5327), PLG(5340)
Biochem/physiol Actions
赖氨酸类似物。促进纤溶酶的快速解离，从而抑制纤溶酶原的活化和随后的纤维蛋白溶解。
赖氨酸类似物。促进纤溶酶的快速解离，从而抑制纤溶酶原的活化和随后的纤维蛋白溶解。据报道可抑制纤溶酶原与活化的血小板结合。 早期报告表明，它抑制补体系统第一成分的激活。结合羧肽酶 B并使其灭活。
Still not finding the right product?
Explore all of our products under 6-氨基己酸
存储类别
11 - Combustible Solids
wgk
WGK 2
ppe
dust mask type N95 (US), Eyeshields, Gloves
flash_point_f
404.6 - 408.2 °F
flash_point_c
207 - 209 °C
法规信息
新产品
此项目有
Illa Ramakanth et al.
The journal of physical chemistry. B, 116(9), 2722-2729 (2012-02-09)
A two-component gel resulting from the amphiphilic cationic surfactant cetylpyridinium chloride (CPC) in the presence of a structure-forming bola-amphiphilic additive 6-aminocaproic acid (6-ACA) was realized and investigated. At a critical 6 wt % of 1:1 CPC:6-ACA, the yellow colored gel
Andrew B Jackson et al.
Nuclear medicine and biology, 39(3), 377-387 (2012-01-10)
The present study describes the design and development of a new heterodimeric RGD-bombesin (BBN) agonist peptide ligand for dual receptor targeting of the form (64)Cu-NO2A-RGD-Glu-6-Ahx-BBN(7-14)NH(2) in which Cu-64=a positron emitting radiometal; NO2A=1,4,7-triazacyclononane-1,4-diacetic acid; Glu=glutamic acid; 6-Ahx=6-aminohexanoic acid; RGD=the amino acid
Brian Hutton et al.
BMJ (Clinical research ed.), 345, e5798-e5798 (2012-09-13)
To estimate the relative risks of death, myocardial infarction, stroke, and renal failure or dysfunction between antifibrinolytics and no treatment following the suspension of aprotinin from the market in 2008 for safety reasons and its recent reintroduction in Europe and